Takahito Negishi1, Nobuki Furubayashi2, Tohru Nakagawa3, Naotaka Nishiyama4, Hiroshi Kitamura4, Yoshifumi Hori5, Kentarou Kuroiwa5, Yuhyon Son6, Narihito Seki6, Toshihisa Tomoda7, Eijiro Okajima8, Motonobu Nakamura2. 1. Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; n2takajin@gmail.com. 2. Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. 3. Department of Urology, Teikyo University School of Medicine, Tokyo, Japan. 4. Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research University of Toyama, Toyama, Japan. 5. Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan. 6. Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan. 7. Department of Urology, Oita Prefectural Hospital, Oita, Japan. 8. Department of Urology, Nara City Hospital, Nara, Japan.
Abstract
BACKGROUND/AIM: Nivolumab monotherapy for advanced/metastatic renal cell carcinoma (RCC) shows a survival benefit. The purpose of this study was to evaluate tumor responses to nivolumab in various metastatic and primary sites in patients with RCC. PATIENTS AND METHODS: We retrospectively reviewed 68 patients who underwent nivolumab monotherapy after one or more regimens of targeted therapy for advanced/metastatic RCC. The site-specific response was evaluated and progression-free survival was estimated. RESULTS: The site-specific overall response rates (ORRs) were as follows: lung (36%), bone (5%), lymph node (33%), liver (50%), adrenal gland (29%), pancreas (33%), and brain (0%). The ORR of bone metastasis was significantly worse in comparison to lung and liver metastases (p=0.017, 0.008). The site-specific median progression-free survival times were as follows: lung (5.1 months), bone (not reached), lymph node (not reached), and liver (17.5 months). CONCLUSION: Responses to nivolumab may vary depending on metastasized organs.
BACKGROUND/AIM: Nivolumab monotherapy for advanced/metastatic renal cell carcinoma (RCC) shows a survival benefit. The purpose of this study was to evaluate tumor responses to nivolumab in various metastatic and primary sites in patients with RCC. PATIENTS AND METHODS: We retrospectively reviewed 68 patients who underwent nivolumab monotherapy after one or more regimens of targeted therapy for advanced/metastatic RCC. The site-specific response was evaluated and progression-free survival was estimated. RESULTS: The site-specific overall response rates (ORRs) were as follows: lung (36%), bone (5%), lymph node (33%), liver (50%), adrenal gland (29%), pancreas (33%), and brain (0%). The ORR of bone metastasis was significantly worse in comparison to lung and liver metastases (p=0.017, 0.008). The site-specific median progression-free survival times were as follows: lung (5.1 months), bone (not reached), lymph node (not reached), and liver (17.5 months). CONCLUSION: Responses to nivolumab may vary depending on metastasized organs.